Tissue Engineering and Biomaterial-Based Regenerative Medicine Market Size, Share, Trends, Industry Analysis Report By Application (Musculoskeletal, Kidney, Liver), By Region – Market Forecast, 2025–2034
Description
The tissue engineering and biomaterial-based regenerative medicine market size is expected to reach USD 8,879.48 million by 2034, according to a new study by Polaris Market Research. The report “Tissue Engineering and Biomaterial-Based Regenerative Medicine Market Size, Share, Trends, Industry Analysis Report By Application (Musculoskeletal, Kidney, Liver), By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Regenerative medicine is proving to be a valuable treatment option for chronic and clinical medical conditions. Tissue engineering and regenerative medicine have greatly evolved in the recent past and have undergone rapid changes. Tissue engineering is now being considered as an effective tool to treat organ related health issues, through the combination of scaffolds, cells, and biologically active molecules.
The move toward personalized healthcare is driving demand for regenerative treatments that can be customized to individual patients. Using a patient’s own cells to grow tissues or organs significantly reduces the chances of rejection and improves healing outcomes. Advanced biomaterials can now be engineered to match the mechanical and biological needs of each person, making treatments more effective. This trend toward precision medicine is aligning perfectly with the core capabilities of tissue engineering, thereby driving the growth.
The global shortage of donor organs and tissues has led to an urgent search for alternatives. Tissue engineering offers a promising solution by enabling the development of lab-grown tissues and organs using the patient’s own cells. This reduces the risks of rejection and long waiting times. Biomaterial-based scaffolds help support cell growth and tissue formation, providing a foundation for successful transplants. The need for regenerative medicine technologies becomes even more critical as the gap between supply and demand for transplants continues to widen, fueling market growth.
Tissue Engineering and Biomaterial-Based Regenerative Medicine Market Report Highlights
The musculoskeletal segment is anticipated to register a CAGR of 31.5% during the forecast period, driven by the high prevalence of bone, joint, and cartilage-related disorders across the global population.
The kidney segment is expected to hold a notable share of the market, supported by the rising incidence of chronic kidney disease and kidney failure worldwide.
North America dominated the tissue engineering and biomaterial-based regenerative medicine market in 2024, accounting for 55.80% of the global revenue, fueled by its advanced healthcare infrastructure, strong research ecosystem, and substantial healthcare expenditures.
The Asia Pacific market is projected to register a CAGR of 32.3% during the forecast period, driven by increasing healthcare demand, rapid development of medical infrastructure, and rising investment in biotechnology research.
A few key players in the global tissue engineering and biomaterial-based regenerative medicine market are Aspect Biosystems Ltd.; Histogenics Corporation; MiMedx Group, Inc.; Organovo Holdings Inc.; Osiris Therapeutics, Inc.; Takara Bio Inc.; Tissue Regenix Group plc; and Vericel Corporation.
Polaris Market Research has segmented the tissue engineering and biomaterial-based regenerative medicine market report based on application and region:
By Application (Revenue - USD Million, 2020–2034)
Musculoskeletal
Kidney
Liver
By Regional Outlook (Revenue - USD Million, 2020–2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Regenerative medicine is proving to be a valuable treatment option for chronic and clinical medical conditions. Tissue engineering and regenerative medicine have greatly evolved in the recent past and have undergone rapid changes. Tissue engineering is now being considered as an effective tool to treat organ related health issues, through the combination of scaffolds, cells, and biologically active molecules.
The move toward personalized healthcare is driving demand for regenerative treatments that can be customized to individual patients. Using a patient’s own cells to grow tissues or organs significantly reduces the chances of rejection and improves healing outcomes. Advanced biomaterials can now be engineered to match the mechanical and biological needs of each person, making treatments more effective. This trend toward precision medicine is aligning perfectly with the core capabilities of tissue engineering, thereby driving the growth.
The global shortage of donor organs and tissues has led to an urgent search for alternatives. Tissue engineering offers a promising solution by enabling the development of lab-grown tissues and organs using the patient’s own cells. This reduces the risks of rejection and long waiting times. Biomaterial-based scaffolds help support cell growth and tissue formation, providing a foundation for successful transplants. The need for regenerative medicine technologies becomes even more critical as the gap between supply and demand for transplants continues to widen, fueling market growth.
Tissue Engineering and Biomaterial-Based Regenerative Medicine Market Report Highlights
The musculoskeletal segment is anticipated to register a CAGR of 31.5% during the forecast period, driven by the high prevalence of bone, joint, and cartilage-related disorders across the global population.
The kidney segment is expected to hold a notable share of the market, supported by the rising incidence of chronic kidney disease and kidney failure worldwide.
North America dominated the tissue engineering and biomaterial-based regenerative medicine market in 2024, accounting for 55.80% of the global revenue, fueled by its advanced healthcare infrastructure, strong research ecosystem, and substantial healthcare expenditures.
The Asia Pacific market is projected to register a CAGR of 32.3% during the forecast period, driven by increasing healthcare demand, rapid development of medical infrastructure, and rising investment in biotechnology research.
A few key players in the global tissue engineering and biomaterial-based regenerative medicine market are Aspect Biosystems Ltd.; Histogenics Corporation; MiMedx Group, Inc.; Organovo Holdings Inc.; Osiris Therapeutics, Inc.; Takara Bio Inc.; Tissue Regenix Group plc; and Vericel Corporation.
Polaris Market Research has segmented the tissue engineering and biomaterial-based regenerative medicine market report based on application and region:
By Application (Revenue - USD Million, 2020–2034)
Musculoskeletal
Kidney
Liver
By Regional Outlook (Revenue - USD Million, 2020–2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
125 Pages
- Chapter 1. Introduction
- 1.1 Report Description
- 1.1.1 Objectives of the Study
- 1.1.2 Market Scope
- 1.1.3 Assumptions
- 1.2 Stakeholders
- Chapter 2. Executive Summary
- 2.1 Market Highlights
- Chapter 3. Research Methodology
- 3.1 Overview
- 3.1.1 Data Mining
- 3.2 Data Sources
- 3.2.1 Primary Sources
- 3.2.2 Secondary Sources
- Chapter 4. Tissue Engineering and Biomaterial-Based Regenerative Medicine Market Insights
- 4.1 Tissue Engineering and Biomaterial-Based Regenerative Medicine – Industry snapshot
- 4.2 Tissue Engineering and Biomaterial-Based Regenerative Medicine Market Dynamics
- 4.2.1 Drivers and Opportunities
- 4.2.1.1 Rising Investments across the globe
- 4.2.1.1.1 Examples of key financing initiatives, 2024
- 4.2.1.1.2 Total Global Financings Type by Year
- 4.2.1.2 Widening Global Clinical Landscape
- 4.2.1.3 Technological advancements in scaffold technology
- 4.2.1.4 Increasing demand for body reconstruction procedures and tissue engineering
- 4.2.1.5 Increasing demand for body reconstruction procedures and tissue engineering
- 4.2.2 Restraints and Challenges
- 4.2.2.1 Comparatively High Cost
- 4.2.2.2 Inconsistency in data generated
- 4.2.2.3 Advent of scaffold-free technology
- 4.3 Porter’s Five Forces Analysis
- 4.3.1 Bargaining Power of Suppliers (High)
- 4.3.2 Threats of New Entrants: (Low)
- 4.3.3 Bargaining Power of Buyers (Moderate)
- 4.3.4 Threat of Substitute (Moderate)
- 4.3.5 Rivalry among existing firms (Moderate)
- 4.4 PEST Analysis
- 4.5 Tissue Engineering and Biomaterial-Based Regenerative Medicine Market – Covid Impact Analysis
- 4.6 Tissue Engineering and Biomaterial-Based Regenerative Medicine Market – Industry Trends
- Chapter 5. Tissue Engineering and Biomaterial-based Regenerative Medicine Market Assessment by Application
- 5.1 Introduction
- 5.2 Musculoskeletal
- 5.3 Kidney
- 5.4 Liver
- Chapter 6. Tissue Engineering and Biomaterial-based Regenerative Medicine Market Assessment by Geography
- 6.1 Introduction
- 6.2 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – North America
- 6.2.1 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – U.S.
- 6.2.2 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – Canada
- 6.3 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – Europe
- 6.3.1 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – Germany
- 6.3.2 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – UK
- 6.3.3 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – France
- 6.3.4 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – Italy
- 6.4 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – Asia Pacific
- 6.4.1 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – China
- 6.4.2 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – Japan
- 6.4.3 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – South Korea
- 6.5 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – Latin America
- 6.6 Tissue Engineering and Biomaterial-based Regenerative Medicine Market – Middle East & Africa
- Chapter 7. Company Profiles
- 7.1 Organovo Holdings Inc.
- 7.1.1 Business Overview
- 7.1.2 Financial Snapshot
- 7.1.3 Products and Services
- 7.1.4 Strategic Initiatives
- 7.2 Tissue Regenix Group plc
- 7.2.1 Business Overview
- 7.2.2 Financial Snapshot
- 7.2.3 Products and Services
- 7.3 Histogenics Corporation
- 7.3.1 Business Overview
- 7.3.2 Products and Services
- 7.4 Aspect Biosystems Ltd.
- 7.4.1 Business Overview
- 7.4.2 Products and Services
- 7.4.3 Strategic Initiatives
- 7.5 Vericel Corporation
- 7.5.1 Business Overview
- 7.5.2 Financial Snapshot
- 7.5.3 Products and Services
- 7.5.4 Strategic Initiatives
- 7.6 MiMedx Group, Inc.
- 7.6.1 Business Overview
- 7.6.2 Financial Snapshot
- 7.6.3 Products and Services
- 7.6.4 Strategic Initiatives
- 7.7 Takara Bio Inc.
- 7.7.1 Business Overview
- 7.7.2 Financial Snapshot
- 7.7.3 Products and Services
- 7.7.4 Strategic Initiatives
- 7.8 Osiris Therapeutics, Inc
- 7.8.1 Business Overview
- 7.8.2 Products and Services
- 7.8.3 Strategic Initiatives
- Chapter 8. Customization
- 8.1 Approximate Market Share of Major Applications in Tissue Engineering Market
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.